Read articles from Global

August 07, 2026 by frontiersin.org

Smoking is a major but often neglected driver of poor health among people with schizophrenia spectrum disorders. A 2026 scoping review found preliminary evidence that e-cigarette interventions may be feasible and acceptable in this group, with signs of smoking reduction, short-term abstinence and reduced exposure to tobacco-related carcinogens. The evidence is still limited, with only a small number of studies and important questions about long-term support and generalisability. But for a population where conventional cessation often performs poorly, harm reduction deserves serious clinical attention.

August 07, 2026 by springer.com

Affordability can decide whether harm reduction is realistic or theoretical. A cross-country analysis of 55 countries found that heated tobacco products are often less affordable than cigarettes, especially in lower-income settings and among lower-income groups. That matters because price shapes behaviour: if lower-risk alternatives cost more than cigarettes, switching becomes harder for the people who may need it most. Tobacco policy should look beyond tax rates alone and consider the real consumer price of moving away from combustion.

August 06, 2026 by gfn.tv

Prohibition often promises fewer problems, but the aftermath tells a different story. Once safer nicotine products are pushed out of legal reach, people do not simply stop wanting them — they find other routes, often with less oversight and more risk. For smokers, that can mean returning to cigarettes or relying on unregulated supply. The real test is not whether prohibition sounds protective, but whether it leaves people safer than before.

August 05, 2026 by substack.com

Every cigarette avoided is a risk reduction, even when the alternative is not risk-free. That is the point often lost in vaping debates. For adults who smoke, the comparison should begin with continued exposure to combustion, not an impossible standard of harmlessness. Public health should ask which choices reduce harm in real life, not which ones fit a perfect abstinence model.

August 05, 2026 by thehill.com

Flavoured nicotine pouches receiving FDA authorisation complicates the idea that flavour alone should make a product unacceptable. The decision suggests that regulators can assess smoke-free products on evidence, exposure and population-level impact rather than category assumptions. Adult smokers need options that are both lower risk and acceptable enough to support switching. If authorisation is based on science, policy should allow that science to be communicated clearly.

August 05, 2026 by businesstech.co.za

Recognising that nicotine products differ in risk is only the first step. The harder task is ensuring that legislation reflects that distinction in practice. When smoke-free products are regulated as though they are equivalent to combustible cigarettes, policy loses the opportunity to encourage lower-risk choices while maintaining strong safeguards for young people. Evidence-based regulation should distinguish products according to their risk profile, not simply group them under the same label.

August 04, 2026 by substack.com

Quitting nicotine and quitting smoking are not the same public health outcome. A person may continue using nicotine while dramatically reducing exposure to the toxicants created by burning tobacco. That distinction matters because insisting on nicotine abstinence as the only acceptable goal can overlook meaningful reductions in disease risk. For many smokers, the first priority should be leaving combustion behind — even if nicotine use does not end immediately.

August 04, 2026 by substack.com

Sometimes harm reduction begins with one person who refuses to give up on someone else. Behind the evidence, policy arguments and product categories are people who smoke, people who love them, and people trying to keep them alive long enough to find a safer path. Tobacco harm reduction is often discussed as a technical issue, but its urgency is deeply human. The goal is not to win an argument about nicotine — it is to reduce harm for real people.

August 04, 2026 by gfn.tv

Stability may sound like a technical detail, but it shapes whether a nicotine pouch performs consistently over time. Formula design can affect nicotine release, shelf life, user experience and the standards regulators should expect from smoke-free products. That makes product chemistry part of the public health conversation, not just a manufacturing issue. If nicotine pouches are to be regulated responsibly, evidence on formulation and stability should matter as much as assumptions about the category.

August 03, 2026 by vapingpost.com

A nicotine pouch is not a cigarette without smoke; it is a different product category altogether. That distinction matters for regulation, because rules designed around combustion do not automatically make sense for oral, smoke-free nicotine. Pouches still need standards, age controls and monitoring, but policy should reflect their actual risk profile rather than the stigma attached to cigarettes. Regulation is most credible when it recognises differences instead of flattening them.